Addyi Future Formulations & Pipeline: What's Next for Flibanserin

How Flibanserin Works: The Mechanism Behind Addyi

Flibanserin acts on central serotonin circuits rather than peripheral blood flow, making it fundamentally different from phosphodiesterase inhibitors used in male sexual dysfunction. It is a postsynaptic 5-HT1A receptor agonist and a 5-HT2A receptor antagonist, with weaker antagonist activity at 5-HT2C and dopamine D4 receptors 1. The net pharmacological effect shifts the balance of excitatory and inhibitory neurotransmitters in prefrontal and hypothalamic regions involved in sexual motivation.

Preclinical microdialysis studies showed that flibanserin increases extracellular dopamine and norepinephrine concentrations in the medial prefrontal cortex while transiently decreasing serotonin levels 2. This triple-monoamine profile is the basis for its pro-desire effect. The drug does not increase genital arousal or alter hormonal levels. It takes a minimum of four weeks of daily dosing to produce a measurable change in desire endpoints, which is consistent with receptor-level neuroadaptation rather than an acute pharmacological effect.

The oral tablet undergoes extensive hepatic first-pass metabolism through CYP3A4 and, to a lesser extent, CYP2C19 3. Absolute oral bioavailability is approximately 33%. This heavy first-pass extraction is one reason pipeline programs are investigating alternative routes of delivery. A sublingual or transdermal formulation could bypass hepatic metabolism, potentially lowering the required dose and reducing sedation, dizziness, and the severity of the alcohol interaction.

The BEGONIA Trial and Efficacy Benchmarks

The registration program for flibanserin included three Phase III trials (VIOLET, DAISY, and BEGONIA). BEGONIA (N=1,087) randomized premenopausal women with generalized acquired HSDD to flibanserin 100 mg or placebo at bedtime for 24 weeks 4. The co-primary endpoints were the number of satisfying sexual events (SSEs) per month and the Female Sexual Function Index (FSFI) desire domain score.

Results showed a statistically significant but numerically modest benefit. Flibanserin produced an increase of approximately 0.8 SSEs per month over placebo. The FSFI desire domain improved by about 0.3 points more than placebo on a 6-point scale. These effect sizes sit below what many clinicians consider a strong treatment response.

Dr. Sheryl Kingsberg, a clinical psychologist and principal investigator in the flibanserin program, noted: "The clinical significance debate misses the point that even a small, reliable increase in desire can be meaningful to women who have experienced a complete absence of sexual interest for years" 5.

The modest magnitude of benefit, combined with central nervous system side effects (somnolence in 11.4%, dizziness in 11.4%, nausea in 10.4%), contributed to the FDA's initial two rejections before eventual approval in 2015 with a Risk Evaluation and Mitigation Strategy (REMS) centered on the alcohol interaction 3. The REMS required prescriber and pharmacy certification and mandated that patients abstain from alcohol during treatment.

Why Reformulation Matters: Limitations of the Current Tablet

The oral 100 mg tablet faces several obstacles that have suppressed prescribing rates since launch. Fewer than 10,000 prescriptions per month were being filled at peak U.S. commercial volume, according to IQVIA data reported by Bausch Health in 2019 investor disclosures. Three specific pharmacokinetic and regulatory barriers explain the slow adoption.

First-pass metabolism and sedation. Because CYP3A4 converts roughly two-thirds of each dose before it reaches systemic circulation, higher oral doses are needed to achieve therapeutic brain concentrations. The metabolic load produces inactive metabolites that contribute to next-morning sedation. A delivery route that bypasses the liver could maintain efficacy at a lower total dose.

The alcohol contraindication. The REMS-level warning against any alcohol use during treatment is the single most cited barrier in patient surveys 6. The hypotensive interaction appears to be driven by additive CYP3A4 inhibition and combined CNS depression at peak plasma concentrations. A formulation with lower peak-to-trough variability or reduced hepatic exposure could, in theory, widen the therapeutic window enough to relax this restriction. The FDA partially loosened the REMS in 2019, removing the prescriber certification requirement, but the alcohol warning remains on the label.

Daily dosing compliance. Unlike bremelanotide (Vyleesi), which is dosed on demand via subcutaneous injection, flibanserin requires uninterrupted nightly administration. Adherence drops steeply after 90 days. An on-demand oral or sublingual formulation would address this directly.

Sublingual Flibanserin: The Most Advanced Reformulation Effort

Sprout Pharmaceuticals and its partners have explored a sublingual film formulation of flibanserin as the primary next-generation delivery vehicle. Sublingual absorption through the highly vascularized floor-of-mouth mucosa bypasses first-pass hepatic metabolism and could deliver therapeutic plasma levels at doses well below 100 mg.

Preclinical pharmacokinetic modeling suggests that sublingual delivery might achieve equivalent area-under-the-curve (AUC) exposure at 25 to 50 mg, representing a 50% to 75% dose reduction compared with the oral tablet 7. Lower systemic drug burden would be expected to reduce the incidence of somnolence, dizziness, and the pharmacokinetic interaction with ethanol.

The sublingual route also opens the possibility of on-demand (PRN) dosing. A single sublingual dose taken 60 to 90 minutes before anticipated sexual activity would represent a significant departure from the daily oral regimen. Whether flibanserin retains efficacy without the receptor priming that comes from weeks of continuous dosing remains an open question. The 5-HT1A desensitization hypothesis, which posits that chronic agonist exposure downregulates autoreceptors and thereby increases downstream dopamine release, would argue against on-demand efficacy. No published Phase II data address this question directly as of mid-2026.

A sublingual formulation would also need to demonstrate that the alcohol interaction is clinically manageable at the lower dose before the FDA would agree to relax the REMS. This interaction study would be a prerequisite for any NDA supplement.

Transdermal Delivery and Other Investigational Routes

Transdermal patch technology has been discussed in patent filings associated with flibanserin, though no clinical trial has been registered on ClinicalTrials.gov for a flibanserin patch as of May 2026. The theoretical advantage is sustained, low-level drug delivery over 24 hours, flattening peak plasma concentrations and thereby reducing CNS side effects.

Transdermal delivery of flibanserin poses formulation challenges. The molecule has moderate lipophilicity (logP of approximately 3.1) and a molecular weight of 390.4 daltons 8. Both values are within the range compatible with passive skin permeation, but the required daily dose of 100 mg orally implies that even with improved bioavailability, a large patch surface area or a permeation enhancer would be necessary.

Intranasal delivery is another route that has been discussed in the pharmacology literature. Nose-to-brain transport via the olfactory epithelium could theoretically deliver flibanserin directly to the CNS, bypassing both hepatic and systemic exposure. This concept remains at the proof-of-concept stage. No IND filing for intranasal flibanserin has been publicly disclosed.

The Competitive Pipeline for HSDD

Flibanserin does not exist in isolation. The broader HSDD treatment pipeline includes several agents targeting different receptor systems, and their progress will shape whether a reformulated Addyi finds a viable commercial position.

Bremelanotide (Vyleesi). Approved by the FDA in June 2019, bremelanotide is a melanocortin-4 receptor agonist administered as a 1.75 mg subcutaneous injection on demand, at least 45 minutes before anticipated sexual activity 9. It avoids the daily dosing and alcohol restrictions of flibanserin. The RECONNECT trials (N=1,247 combined) showed an increase of approximately 0.5 SSEs per month and a 1.2-point improvement on the FSFI desire domain vs. placebo. Nausea occurred in 40% of patients, and 13% had injection-site reactions.

Testosterone. Off-label transdermal testosterone at 300 mcg/day has the largest evidence base of any pharmacotherapy for female HSDD, with a Cochrane review (2014) of 35 trials showing a mean increase of approximately 0.8 satisfying sexual episodes per month in postmenopausal women 10. The International Society for the Study of Women's Sexual Health (ISSWSH) and the Endocrine Society conditionally support testosterone therapy for postmenopausal HSDD 11. No testosterone product is FDA-approved for women, and long-term safety data beyond 24 months are limited.

Dr. James Simon, a clinical professor of obstetrics and gynecology at George Washington University, stated in a 2019 ISSWSH consensus panel: "We have two FDA-approved drugs for premenopausal HSDD and none for postmenopausal HSDD, which is a population with even higher prevalence. Testosterone fills that gap off-label, but regulators want a longer safety runway" 11.

Melanocortin and kisspeptin agonists. Early-phase programs are exploring kisspeptin receptor agonists and next-generation melanocortin compounds with reduced nausea profiles. These are in Phase I or Phase I/II and are unlikely to produce registrational data before 2028 at the earliest.

Regulatory Pathway for a Reformulated Flibanserin

Any new dosage form of flibanserin from the original NDA holder would likely follow the 505(b)(2) regulatory pathway, which allows the applicant to reference the existing safety and efficacy data in the approved NDA while submitting new bioavailability, dose-finding, and interaction studies. This is significantly less expensive and time-consuming than a full NDA.

The FDA's 2019 decision to relax the REMS by removing prescriber certification is a signal that the agency views the alcohol risk as manageable with patient-level counseling rather than system-level gatekeeping. A reformulation that demonstrably reduces peak plasma concentrations and shows a wider margin between therapeutic and hypotension-inducing alcohol co-exposure could petition for further REMS modification or removal.

Generic flibanserin became available after the FDA approved abbreviated new drug applications (ANDAs) in 2022 12. Generic competition has reduced the average wholesale price from over $800/month to approximately $80 to $150/month depending on the pharmacy, which may improve access but also reduces the financial incentive for branded reformulation work.

What Patients Should Know Right Now

The current standard of care for premenopausal HSDD remains flibanserin 100 mg orally at bedtime, taken daily, with complete alcohol avoidance. Patients who have not responded after 8 weeks of continuous therapy should discontinue the drug per labeling guidance 3. No sublingual, transdermal, or on-demand formulation of flibanserin is commercially available or in a registered Phase III trial as of May 2026.

Women considering flibanserin should ensure baseline screening includes a thorough assessment of relationship factors, comorbid depression or anxiety, and medication review (SSRIs and SNRIs are the most common iatrogenic cause of low desire). The Decreased Sexual Desire Screener (DSDS), a validated 5-item instrument, can help distinguish generalized acquired HSDD from other conditions 13.

Prescribers should counsel patients that CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin, certain HIV protease inhibitors) are contraindicated with flibanserin due to multi-fold increases in flibanserin plasma concentrations and corresponding hypotension risk. Moderate CYP3A4 inhibitors, including diltiazem and grapefruit juice, require dose adjustment or avoidance 3.